Clinical experience with tocilizumab in the treatment of pregnant woman with severe COVID-19
DOI:
https://doi.org/10.14739/2310-1237.2022.1.253286Keywords:
coronavirus disease, COVID-19, infectious pregnancy complications, tocilizumabAbstract
The aim of the work – to present a case of positive use of tocilizumab in the treatment of pregnant woman with severe COVID-19.
Materials and methods. A self-observation clinical case of severe coronavirus disease (COVID-19) in pregnant K., 40 years old, who was treated at Municipal Non-Profit Enterprise “Regional Infectious Diseases Clinical Hospital” of Zaporizhzhia Regional Council. The patient was treated in accordance with the “Protocol for the provision of medical care for the treatment of coronavirus disease (COVID-19)”.
Results. Our own clinical observation demonstrates the formation of severe COVID-19 in a 40-year-old pregnant woman in the second trimester of pregnancy. Combination treatment with glucocorticoids in the presence of oxygen dependence on the 11th day of the disease was ineffective for two days of clinical and laboratory parameters monitoring, which required a decision on the additional appointment of tocilizumab. The development of “cytokine storm” clinical and laboratory signs on the 12th day of the disease was evidenced by the preservation of fever in the range of 37.5–37.8 °C, no regression of oxygen dependence. According to laboratory data, an increase in the severity of lymphopenia as a relative quantity – up to 5 % and absolute quantity – up to 0.5 × 109/l, an increase in fibrinogen – up to 5.8 g/l and D-dimer – up to 1.9 ng/ml, high level of C-reactive protein – up to 190 mg/l. These data justify the additional use of tocilizumab, which was administered at a dose of 8 mg/kg in the absence of contraindications. Tocilizumab administration was effective, contributing to oxygen dependence regression and recovery of laboratory parameters within a week.
Conclusions. Our own clinical observation demonstrates the formation of severe COVID-19 in pregnant woman in the second trimester of pregnancy. Due to the ineffectiveness of glucocorticosteroid therapy and the presence of clear clinical and laboratory signs of “cytokine storm” on the 12th day of the disease, the use of tocilizumab was effective, which contributed to the oxygen dependence regression and recovery of laboratory parameters within a week. Treatment of pregnant woman with severe COVID-19 requires adherence to existing protocols.
References
Racicot, K., & Mor, G. (2017). Risks associated with viral infections during pregnancy. Journal of Clinical Investigation, 127(5), 1591-1599. https://doi.org/10.1172/jci87490
Hantoushzadeh, S., Shamshirsaz, A. A., Aleyasin, A., Seferovic, M. D., Aski, S. K., Arian, S. E., Pooransari, P., Ghotbizadeh, F., Aalipour, S., Soleimani, Z., Naemi, M., Molaei, B., Ahangari, R., Salehi, M., Oskoei, A. D., Pirozan, P., Darkhaneh, R. F., Laki, M. G., Farani, A. K., … Aagaard, K. (2020). Maternal death due to covid-19. American Journal of Obstetrics and Gynecology, 223(1). https://doi.org/10.1016/j.ajog.2020.04.030
Li, J., Wang, Y., Zeng, Y., Song, T., Pan, X., Jia, M., He, F., Hou, L., Li, B., He, S., & Chen, D. (2020). Critically ill pregnant patient with Covid-19 and neonatal death within two hours of birth. International journal of gynaecology and obstetrics, 150(1), 126-128. https://doi.org/10.1002/ijgo.13189
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick, D., Rege, K., Fegan, C., Chappell, L. C., Faust, S. N., Jaki, T., … Landray, M. J. (2020). Effect of dexamethasone in hospitalized patients with COVID-19 – preliminary report. https://doi.org/10.1101/2020.06.22.20137273
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/
Ministry of Healthcare of Ukraine. (2020, April 2). Protokol "Nadannia medychnoi dopomohy dlia likuvannia koronavirusnoi khvoroby (COVID-19)" [Protocol for the provision of medical care for the treatment of coronavirus disease (COVID-19) (No. 762)]. [in Ukrainian]. https://zakon.rada.gov.ua/rada/show/v0762282-20?lang=en#Text
Tolcher, M. C., McKinney, J. R., Eppes, C. S., Muigai, D., Shamshirsaz, A., Guntupalli, K. K., & Nates, J. L. (2020). Prone positioning for pregnant women with hypoxemia due to coronavirus disease 2019 (COVID-19). Obstetrics & Gynecology, 136(2), 259-261. https://doi.org/10.1097/aog.0000000000004012
Rahmati, M. (2020). Cytokine-targeted therapy in severely ill covid-19 patients: Options and cautions. Eurasian Journal of Medicine and Oncology, 4(2), 179-180. https://doi.org/10.14744/ejmo.2020.72142
Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2015). Tocilizumab in early progressive rheumatoid arthritis: Function, a randomised controlled trial. Annals of the Rheumatic Diseases, 75(6), 1081-1091. https://doi.org/10.1136/annrheumdis-2015-207628
Furst, D. E. (2004). Anakinra: Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clinical Therapeutics, 26(12), 1960-1975. https://doi.org/10.1016/j.clinthera.2004.12.019
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, C.-C. V., Edwards, K. M., Gandhi, R., Gallagher, J., Muller, W. J., O’Horo, J. C., Shoham, S., Murad, M. H., Mustafa, R. A., Sultan, S., & Falck-Ytter, Y. (2020). Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
National Institute for Health and Care Excellence. (2021, March 23). COVID-19 rapid guideline: managing COVID-19: Guidance NG191. NICE. https://www.nice.org.uk/guidance/ng191
Okoh, A. K., Bishburg, E., Grinberg, S., & Nagarakanti, S. (2021). Tocilizumab use in COVID-19-associated pneumonia. Journal of medical virology, 93(2), 1023-1028. https://doi.org/10.1002/jmv.26471
Lan, S.-H., Lai, C.-C., Huang, H.-T., Chang, S.-P., Lu, L.-C., & Hsueh, P.-R. (2020). Tocilizumab for severe COVID-19: A systematic review and meta-analysis. International Journal of Antimicrobial Agents, 56(3), 106103. https://doi.org/10.1016/j.ijantimicag.2020.106103
Hermine, O., Mariette, X., Tharaux, P.-L., Resche-Rigon, M., Porcher, R., Ravaud, P., Bureau, S., Dougados, M., Tibi, A., Azoulay, E., Cadranel, J., Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F., Pourchet-Martinez, V., … Renet, S. (2021). Effect of tocilizumab vs usual care in adults hospitalized with covid-19 and moderate or severe pneumonia. JAMA Internal Medicine, 181(1), 32. https://doi.org/10.1001/jamainternmed.2020.6820
Atal, S., & Fatima, Z. (2020). IL-6 inhibitors in the treatment of serious covid-19: A promising therapy? Pharmaceutical Medicine, 34(4), 223-231. https://doi.org/10.1007/s40290-020-00342-z
Riabokon, O. V., Cherkaskyi, V. V., Onishchenkо, T. Y., & Riabokon, Y. Y. (2021). Features of comorbid pathology spectrum and age structure of oxygen-dependent patients with severe coronavirus disease 2019 (COVID-19) depending on outcomes of the disease. Zaporozhye Medical Journal, 23(2), 214-219. https://doi.org/10.14739/2310-1210.2021.2.228712
Vizir, V. A., Sadomov, A. S., & Demidenko, O. V. (2021). Use of tocilizumab in the combination treatment of a COVID-19 patient with concomitant rheumatoid arthritis (a case report). Zaporozhye Medical Journal, 23(5), 739-748. https://doi.org/10.14739/2310-1210.2021.5.232322
Naqvi, M., Zakowski, P., Glucksman, L., Smithson, S., & Burwick, R. M. (2020). Tocilizumab and Remdesivir in a pregnant patient with coronavirus disease 2019 (COVID-19). Obstetrics & Gynecology, 136(5), 1025-1029. https://doi.org/10.1097/aog.0000000000004050
Wei, S.-Q., Fraser, W., & Luo, Z.-C. (2010). Inflammatory cytokines and spontaneous preterm birth in asymptomatic women. Obstetrics & Gynecology, 116(2), 393-401. https://doi.org/10.1097/aog.0b013e3181e6dbc0
Allotey, J., Stallings, E., Bonet, M., Yap, M., Chatterjee, S., Kew, T., Debenham, L., Llavall, A. C., Dixit, A., Zhou, D., Balaji, R., Lee, S. I., Qiu, X., Yuan, M., Coomar, D., Sheikh, J., Lawson, H., Ansari, K., van Wely, M., van Leeuwen, E., … for PregCOV-19 Living Systematic Review Consortium (2020). Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ (Clinical research ed.), 370, m3320. https://doi.org/10.1136/bmj.m3320
Cohen, J., Vignaux, O., & Jacquemard, F. (2020). Covid-19 in pregnant women: General Data from a French national survey. European Journal of Obstetrics & Gynecology and Reproductive Biology, 251, 267-268. https://doi.org/10.1016/j.ejogrb.2020.06.002
Khoury, R., Bernstein, P. S., Debolt, C., Stone, J., Sutton, D. M., Simpson, L. L., Limaye, M. A., Roman, A. S., Fazzari, M., Penfield, C. A., Ferrara, L., Lambert, C., Nathan, L., Wright, R., Bianco, A., Wagner, B., Goffman, D., Gyamfi-Bannerman, C., Schweizer, W. E., … Dolan, S. M. (2020). Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection at five New York City medical centers. Obstetrics & Gynecology, 136(2), 273-282. https://doi.org/10.1097/aog.0000000000004025
Pierce-Williams, R. A. M., Burd, J., Felder, L., Khoury, R., Bernstein, P. S., Avila, K., Penfield, C. A., Roman, A. S., DeBolt, C. A., Stone, J. L., Bianco, A., Kern-Goldberger, A. R., Hirshberg, A., Srinivas, S. K., Jayakumaran, J. S., Brandt, J. S., Anastasio, H., Birsner, M., O’Brien, D. S., … Berghella, V. (2020). Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: A united states cohort study. American Journal of Obstetrics & Gynecology MFM, 2(3), 100134. https://doi.org/10.1016/j.ajogmf.2020.100134
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
